Cardiovascular

FDA approves Omontys for anemia in dialysis patients

On March 29, the U.S. Food and Drug Administration (FDA) approved Omontys (peginesatide) to treat anemia in adult patients who had chronic kidney disease and are on dialysis. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares